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Abstract
Blood pressure (BP) remains poorly controlled among hypertensive patients with coronary heart disease (CHD) in China.
Improvement of its management will require an understanding of the patient characteristics and treatment factors
associated with uncontrolled hypertension. A cross-sectional survey of 3,279 patients from 52 centers in China was
performed to examine potential barriers to adequate blood pressure control of hypertensive patients with CHD.
Uncontrolled hypertension was defined as blood pressure $130/or 80 mmHg. Multivariable logistic regression was used to
identify factors associated with poor blood pressure control. Mean age of the patients was 65 years, 40% were women, and
mean BMI was 25 kg/m2. Mean systolic blood pressure was 136618 mmHg and mean diastolic blood pressure was
80611 mmHg. Only 18% of patients had a mean blood pressure ,130/80 mmHg during the study period. Multivariate
analysis revealed several independent factors of poor blood pressure control: body mass index $23 kg/m2, the presence of
stable angina pectoris (SAP), family history of diabetes, and use of calcium channel blockers (CCB). Further analysis showed
that non-dihydropyridine calcium antagonist was significantly correlated with low BP control rate. Some of these may be
amenable to modification. The results of our study suggest that overweight, the presence of SAP and family history of
diabetes are important factors for tight BP control in primary care. In addition, non-dihydropyridine calcium channel
blockers appear less effective than other therapies in control of blood pressure and should not be the first choice among
hypertensive patients with CHD. Further identification of patients at risk of poor BP control can lead to targeted
interventions to improve management.
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Introduction
Hypertension is an important risk factor for cardiovascular
disease and has become a major global burden on public health
[1]. In 2002, one-sixth of all Chinese adults were found to be
hypertensive, and in most cases, hypertension was uncontrolled
[2]. In addition, hypertension has often clustered with coronary
heart disease (CHD). For example, 46% of hypertensive patients
had a history of CHD in the Valsartan Antihypertensive Long-
term Use Evaluation (VALUE) trial [3]. Moreover, hypertensive
patients with CHD often had uncontrolled blood pressure (BP) as
well as higher cardiovascular morbidity and mortality. Uncon-
trolled blood pressure could augment cardiovascular risk in
hypertensive individuals with CHD, so it is important to identify
the factors that influence blood pressure control in hypertensive
patients with CHD.
Generally, most guidelines stipulated a blood pressure treatment
goal of 140/90 mmHg. However, recent clinical trials showed
further benefit could be achieved by more aggressive blood
pressure lowering to well below 130/80 mmHg in hypertensive
populations, including those patients with CHD [4,5]. Based on
these recent trials, American Heart Association Scientific State-
ment recommended that this lower blood pressure treatment goal
be expanded to include patients with CHD, stable or unstable
angina pectoris, and myocardial infarction (MI) with or without
ST elevation in 2007 [5]. A blood pressure goal of,130/80 mmHg
is strongly recommended for hypertensive patients with CHD.
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Previous trials did not measure blood pressure control rates
among hypertensive patients with CHD. It will therefore be
important to identify factors that could affect blood pressure
control in hypertensive patients with CHD in a large, nationally
representative sample population. The purpose of this study was to
use data from a previously reported China Cholesterol Education
Program (CCEP) [6] to investigate factors that may influence
blood pressure control in hypertensive patients with CHD in
China.
Methods
Material and Data Collection
The China Cholesterol Education Program (CCEP) was a cross-
sectional, large multicenter investigation, which involved 52
centers in 6 cities (Shanghai, Beijing, Guangzhou, Zhejiang,
Tianjin and Xinjiang) in China [6]. Participants (n = 4778) were
continuously enrolled from January 2006 to January 2007 to
investigate blood lipid levels and the prevalence of achieving the
goal of low-density lipoprotein-cholesterol (LDL-C) level
(,2.6 mmol/L) in Chinese outpatients with CHD. From the
CCEP study, 3279 participants were included for investigation of
blood pressure control and factors that may influence blood
pressure control in hypertensive patients with CHD. Data were
collected by questionnaire including demographic data, medical
history, family history, CHD diagnosis, treatment of CHD and
laboratory examinations. Body mass index (BMI), blood pressure,
fasting plasma glucose, lipids, and smoking status were also
recorded. Blood pressure measurements were taken in the study
clinic by study personnel using a Dinamap XL automated BP
monitor. In Asian population, a BMI cutoff of 23 kg/m2 was
recommended to use to define overweight [7,8]. We, therefore, use
this cut point in our analyses. All participants signed written
informed consent statements allowing access to their medical
records. The data collection protocols were approved by the
Peking University Research Ethics Committee.
Diagnosis of CHD and comorbidities
CHD was diagnosed physicians, and supported by at least one
of the following objective findings; abnormal stress tests (i.e.,
treadmill electrocardiography, cardiac scintigraphy, or stress
echocardiography) indicating significant myocardial ischemia, a
coronary angiogram revealing .50% stenosis of the lumen of any
major coronary artery, a history of confirmed myocardial
infarction (MI) or evidence of prior MI on electrocardiogram, or
a history of a prior coronary revascularization procedure
(percutaneous coronary intervention or coronary artery bypass
graft). The CHD diagnosis was classified as stable angina pectoris
(SAP), previous MI, or acute coronary syndromes (ACS), which
included unstable angina pectoris, ST-segment elevation MI and
non-ST-segment elevation MI [6].
Hypertension was defined as systolic blood pressure
$140 mmHg, and/or diastolic blood pressure $90 mmHg,
and/or current antihypertensive medication [9]. Uncontrolled
hypertension was defined as blood pressure $130/or 80 mmHg.
Diabetes was defined as: (1) fasting plasma glucose concentration
Table 1. Demographic and clinical characteristics hypertensive patients with CHD, CCEP 2006 (N = 3279).
Parameter
Categorical variable n (%)
Female 1309 (40.0%)
Smoking, n (%) 1167 (35.6)
Diabetes mellitus, n (%) 831 (25.3)
Hyperlipidemia, n (%) 1938 (59.1)
Stable angina pectoris, n (%) 1109 (33.8)
Myocardial infarction, n (%) 430 (13.1)
Peripheric atherosclerosis, n (%) 485 (14.8)
Family history of Hypertension, n (%) 1376 (42.0)
Family history of diabetes, n (%) 357 (10.9)
Family history of MI, n (%) 366 (11.2)
Family history of CHD, n (%) 671 (20.5)
Continuous variable mean ±standard deviation
Age (years) 65.81610.78
BMI (kg/m2) 24.7963.13
SBP (mmHg) 136.11617.98
DBP (mmHg) 80.36610.99
TC (mmol/L) 5.0361.51
TG (mmol/L) 2.0061.38
HDL-C (mmol/L) 1.2460.43
LDL-C (mmol/L) 2.9761.01
FPG (mmol/L) 6.0862.79
CCEP: China Cholesterol Education Program; BMI: body mass index; MI: myocardial infarction; CHD: coronary heart disease; SBP: systolic blood pressure; DBP: diastolic
blood pressure; TC: cholesterol; TG: triglyceride; HDL-C: high-density lipoprotein cholesterol; LDL-C: low-density lipoprotein cholesterol; FPG: fasting plasma glucose.
doi:10.1371/journal.pone.0063135.t001
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$7.1 mmol/L in the absence of treatment; (2) glucose concentra-
tion $11.1 mmol/L, 2 h after a 75 g oral glucose load; or (3)
current treatment with hypoglycemic drugs [10]. Peripheral artery
disease was defined as partial or complete atherosclerotic
obstruction of the peripheral arteries on angiography, or
intermittent claudication [11]. Dyslipidemia was defined as total
cholesterol (TC) $5.2 mmol/L, and/or high-density lipoprotein-
cholesterol (HDL-C) #0.90 mmol/L, and/or LDL-C
$3.12 mmol/L, and/or triglyceride (TG) $1.69 mmol/L, or
undergoing current lipid-lowering treatment [6]. Smoking history
was considered positive in those who smoked at least 1 cigarette/
day for at least 1 year [6].
Statistical Analysis
All case record form data were entered into dual Epidata 3.02
databases. The databases were compared and necessary correc-
tions were made. All analyses were performed with the Statistics
Package for Social Science, version 13.0 (Chicago, IL, USA).
Continuous variables are expressed as mean 6 SD, and discrete
variables as percentages. The differences in continuous variables
between groups were examined by t-test. The differences in
discrete variables between groups were calculated by the Pearson
x2 test. Stepwise logistic regression models were used to estimate
the odds ratios (ORs) and associated 95% CI of blood pressure
control, and the probability for variable entry into models was 0.05
and for variable removal was 0.10. The variables that were
significant (P,0.1) in the bivariate analysis were included in a
multivariate logistic regression model. Full model included
BMI$23 kg/m2, stable angina pectoris (SAP), family history of
diabetes, and CCB.
Results
This was a multicenter observational study conducted in the
Chinese society of cardiology. Demographic and clinical charac-
teristics of hypertensive patients with CHD are listed in Table 1.
Among 3279 subjects, the mean age was 65 years, 40% were
women, and mean BMI was 25 kg/m2 (calculated as weight in
kilograms divided by height in meters squared). Table 2 lists all of
treatments and concomitant medication for these patients. The
most common medication use is statin (83% of participants),
followed by b-blockers (64%), CCB (49%), ACEI (46%), ARB
(22%), and diuretics (16%). Figure 1 illustrates that nearly 95% of
individuals were receiving antihypertensive medication, only 18%
individuals achieved tight blood pressure control, and there were
no significant differences of percentages of antihypertensive
therapy use and blood pressure control between men and women
(p.0.05 for both).
The results of bivariate analysis of factors affecting BP control
are shown in Table 3. For hypertensive patients on admission, BP
was optimized according to the guidelines with antihypertensive
drugs (CCB: calcium channel blockers; ACEI: angiotension
converting enzyme inhibitor; ARB: angiotension receptor blocker;
diuretics; b-blockers) to attain normotensive BP values. Multivar-
iate logistic regression analysis showed that the following four
factors were significantly associated with uncontrolled blood
pressure control: higher BMI [OR, 1.426; 95% CI, 1.176–1.729;
P,0.001], the presence of SAP (OR, 1.230; 95% CI, 1.013–1.492;
P,0.036), family history of diabetes (OR, 1.428; 95% CI, 1.035–
1.971; P= 0.030), and use of CCB (OR, 1.360; 95% CI, 1.135–
1.629; P= 0.001) (Table 4). Furthermore, multivariate logistic
regression analysis showed that non-dihydropyridine calcium
antagonist was significantly correlated with low BP control
(Figure 2).
Discussion
The study represents the first analysis of factors that may be
associated with blood pressure control in hypertensive patients
with CHD. We observed that nearly 95% of individuals were
receiving antihypertensive medication, but only 16.7% subjects
(female) and 19.1% (male) had adequate BP control (,130/
80 mmHg). Results from multivariate logistic regression analysis
show that overweight, the presence of SAP, and family history of
diabetes contribute to low BP control rate in these populations.
Further analysis of the data document that non-dihydropyridine
calcium antagonist are also significantly correlated with low BP
control.
Previous meta-regression analysis demonstrated that the benefit
of antihypertensive drug treatment was largely attributable to BP
reduction [12]. Blood Pressure Lowering Treatment Trialists’
Collaboration (BPLTTC) reported that the reduction in CHD and
stroke produced by antihypertensive treatment increased with low
BP targets in studies comparing tight to usual BP control [13], and
other clinical trials have also provided evidence of reduced
incidence of cardiovascular events by bringing blood pressure to
rather low levels in patients with angina pectoris or coronary heart
disease: the EUropean trial on Reduction Of cardiac events with
Perindopril in patients with stable coronary Artery disease
(EUROPA) study: 128/78 rather than 133/80 mm Hg [4]; the
Comparison of Amlodipine vs Enalapril to Limit Occurrences of
Thrombosis (CAMELOT) study: 124/76 rather than 130/
77 mmHg [14]). The European Society of Cardiology (ESC)
Table 2. Medication use among hypertensive patients with
CHD (N= 3279).
Medication use n (%)
Diuretics 534 (16.3)
b-blockers 2089 (63.7)
CCB 1597 (48.7)
ACEI 1506 (45.9)
ARB 829 (25.3)
Statins 2698 (82.3)
CCB+Diuretics 243 (7.4)
CCB+b-blockers 974 (29.7)
CCB+ACEI 606 (18.5)
CCB+ARB 426 (13.0)
CCB+Statins 1327 (40.5)
ACEI+Diuretics 259 (7.9)
ACEI+b-blockers 1036 (31.6)
ACEI+ARB 92 (2.8)
ACEI+Statins 1311 (40.0)
Statins+Diuretics 442 (13.5)
Statins+b-blocker 1801 (54.9)
Statins+ARB 680 (20.7)
Diuretics+b-blockers 327 (10.0)
Diuretics+ARB 202 (6.2)
b-blockers+ARB 504 (15.4)
CHD: coronary heart disease; CCB: calcium channel blockers; ACEI: angiotension
converting enzyme inhibitor; ARB: angiotension receptor blocker.
doi:10.1371/journal.pone.0063135.t002
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2007 guideline recommended that target BP should be at least less
than 130/80 mm Hg in diabetics and in high or very high risk
patients. Data from patients with coronary artery bypass surgery of
the global REduction in Atherothrombosis for Continued Health
(REACH) Registry showed that 76.3% reached BP control
[15].However, only 16.7% subjects (female) and 19.1% (male)
had adequate BP control (,130/80 mmHg) in our patient
population. Therefore, it is important to identify factors that
influence controllability of blood pressure.
In our present study, we found a significant association of
uncontrolled BP with the presence of obesity, SAP and family
history of DM, which were consistent with other previous
publications [16,17]. Cardiac autonomic dysfunction may explain
poor blood pressure control in overweight and obese hypertensive
patients with CHD [16].Actually, these metabolism-related
disorders, mainly with elevated plasma glucose and cholesterol,
would have a considerable impact not only on the atherosclerosis,
such as in patients with CHD, but also on arteriolosclerosis, a
condition with increased arterial stiffness. Recently, in the
Framingham Heart study, arterial stiffness was considered to be
an important and indispensable cause of new-onset hypertension,
but hypertension would not lead to the increased arterial stiffness
[17].Together these studies, our findings indicated that treatment
on either those metabolism-related disorders or arterial stiffness,
would eventually contribute to improved BP control.
Uncontrolled high blood pressure can lead to a variety of
changes in the myocardial structure, coronary vasculature, and
conduction system of the heart. These changes in turn can lead to
the development of left ventricular hypertrophy, coronary artery
disease, and systolic and diastolic dysfunction of the myocardium,
complications that manifest clinically as angina [18]. The role of
family history of DM on uncontrolled BP may be due to the
dietary habit [19]. As we know there is significant association
between poor diet and risk of diabetes, poor diet tends to have
high sodium intake, which was associated poor BP control [20].
Multivariate logistic regression analysis showed poor control of
blood pressure was also associated with use of calcium channel
blockers (CCB). Although several studies have shown improve-
ments in the outcomes of patients with CHD using the
dihydropyridine calcium channel blocker [21,22], there have been
few reports of such vascular protection effects of calcium channel
blockers other than amlodipine. Dihydropyridines tend to be more
potent vasodilators than non-dihydropyridine agents (diltiazem,
verapamil), whereas the latter have marked negative inotropic
effects. Non-dihyrdropyridine calcium channel blockers were
taken more often by uncontrolled than controlled hypertensive
patients [16].Among patients receiving only one drug, non-
Figure 1. Antihypertensive therapy rate and prevalence of blood pressure control.
doi:10.1371/journal.pone.0063135.g001
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dihydropyridine calcium channel blockers are associated with less
nocturnal BP decline than other antihypertensive drug classes,
even after adjusting for the level of risk [23]. These results are
consistent with our study. However, CCB are substances with
potential antianginous properties, used for CHD treatment. Even
if the antihypertensive potential is rather low, it might be a useful
tool in treatment of SAP, certainly not as a first line antihyper-
tensive medication [24].
Table 3. Bivariate analysis of factors affecting blood pressure control in hypertensive patients with CHD.
Controlled (n =595) Uncontrolled (n=2684) P –value
Characteristics
Age (years) 66.57610.60 65.64610.81 0.059
Female, n (%) 219 (36.8) 1090 (40.6) 0.086
BMI$23 kg/m2, n (%) 395 (66.4) 1990 (74.1) ,0.001
Smoking, n (%) 216 (36.3) 951 (35.4) 0.688
Diseases history
Diabetes mellitus, n (%) 162 (27.2) 669 (24.9) 0.221
Myocardial infarction, n (%) 80 (13.5) 350 (13.0) 0.755
Peripheric atherosclerosis, n (%) 88 (14.8) 397 (14.8) 0.999
Hyperlipidemia, n (%) 339 (57.0) 1599 (59.6) 0.309
Stable angina pectoris, n (%) 180 (30.3) 929 (34.6) 0.042
Family history of hypertension, n (%) 240 (40.3) 1136 (42.3) 0.374
Family history of diabetes, n (%) 48 (8.1) 309 (11.5) 0.015
Family history of MI, n (%) 60 (10.1) 306 (11.4) 0.356
Family history of CHD, n (%) 114 (19.2) 557 (20.8) 0.384
Medication use
Diuretics, n (%) 101 (17.0) 433 (16.1) 0.615
b-blocker, n (%) 380 (63.9) 1709 (63.7) 0.930
CCB, n (%) 250 (42.0) 1347 (50.2) ,0.001
ACEI, n (%) 276 (46.4) 1230 (45.8) 0.804
ARB, n (%) 167 (28.1) 662 (24.7) 0.084
Statins, n (%) 507 (85.2) 2191 (81.6) 0.050
CCB+Diuretics, n (%) 34 (5.7) 209 (7.8) 0.081
CCB+b-blocker, n (%) 156 (26.2) 818 (30.5) 0.040
CCB+ACEI, n (%) 93 (15.6) 513 (19.1) 0.048
CCB+ARB, n (%) 68 (11.4) 358 (13.3) 0.210
ACEI+Diuretics, n (%) 41 (6.9) 218 (8.1) 0.314
ACEI+b-blocker, n (%) 193 (32.4) 843 (31.4) 0.625
ACEI+ARB, n (%) 21 (3.5) 71 (2.7) 0.237
Diuretics+b-blocker, n (%) 62 (10.4) 265 (9.9) 0.687
Diuretics+ARB, n (%) 44 (7.4) 158 (5.9) 0.166
b-blocker+ARB, n (%) 100 (16.8) 404 (15.1) 0.283
CHD: coronary heart disease; BMI: body mass index; MI: myocardial infarction; CCB: calcium channel blockers; ACEI: angiotension converting enzyme inhibitor; ARB:
angiotension receptor blocker.
doi:10.1371/journal.pone.0063135.t003
Table 4. Final multivariate model predicting blood pressure control in hypertensive patients with CHD.
Variable OR 95% CIs Lower limit 95% CIs Upper limit P -value
BMI$23 kg/m2 1.426 1.176 1.729 ,0.001
Stable angina pectoris 1.230 1.013 1.492 0.036
Family history of diabetes 1.428 1.035 1.971 0.030
CCB 1.360 1.135 1.629 0.001
CHD: coronary heart disease; BMI: body mass index; CCB: calcium channel blockers; OR: odds ratios; 95% CIs: 95% confidential intervals.
doi:10.1371/journal.pone.0063135.t004
BP Control in Hypertensive Patients with CHD
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The present analysis has several potential limitations. First, the
analysis is cross-sectional, and we cannot determine temporal
direction or causality. Second, because the present analysis is
performed from an aspect differing from the original purpose of
observation, a bias in the selection of patients cannot be excluded.
Another limitation is potential measurement error from the
medication use data. We do not have information on actual
adherence to the treatment regimen. In addition, because the
dosages of CCB including non-dihydropyridine calcium channel
blockers and their continuation states are not investigated, the
effective dosages of CCB could not be clarified. Further studies are
necessary to clarify these points. However, these data have
relevant clinical implications, suggesting that physicians pay close
attention toward the rational use of CCB. The current analysis
also extends our understanding of cross-sectional covariates
associated with hypertensive patients with CHD.
Our data suggest that the presence of obesity, SAP and family
history of diabetes are important factors for tight BP control in
adults with CHD. In addition, non-dihydropyridine calcium
channel blockers may be less effective than other therapies in
control of blood pressure and should not be the first choice among
hypertensive patients with CHD.
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